Disparities in the treatment of movement disorders using deep brain stimulation

• Published in: Journal of neurosurgery Vol. 141; no. 1; p. 241
• Main Authors: Venkatraman, Vishal, Futch, Brittany G, Bode Padron, Kevin J, Yang, Lexie Z, Lee, Hui-Jie, Seas, Andreas, Parente, Beth, Shofty, Ben, Lad, Shivanand P, Williamson, Theresa L, Rahimpour, Shervin
• Format: Journal Article
• Language: English
• Published: United States 01.07.2024
• Subjects: Adult; Aged; Aged, 80 and over; Deep Brain Stimulation; Essential Tremor - therapy; Female; Healthcare Disparities; Humans; Male; Middle Aged; Movement Disorders - therapy; Parkinson Disease - therapy; United States; White People - statistics & numerical data; United States; disparities; essential tremor; functional neurosurgery; healthcare access; Parkinson’s disease; deep brain stimulation
• ISSN: 1933-0693
• DOI: 10.3171/2023.11.JNS23882

Deep brain stimulation (DBS) is a well-established treatment for Parkinson's disease (PD) and essential tremor (ET). Although the prevalence of PD and ET can vary by sex and race, little is known about the accessibility of neurosurgical treatments for these conditions. In this nationwide study, the authors aimed to characterize trends in the use of DBS for the treatment of PD and ET and to identify disparities in the neurosurgical treatment of these diseases based on ethnic, racial, sex, insurance, income, hospital, and geographic factors. Using the dates January 1, 2012, to December 31, 2019, the authors queried the National Inpatient Sample database for all discharges with an ICD-9 or ICD-10 diagnosis of PD or ET. Among these discharges, the DBS rates were reported for each subgroup of race, ethnicity, and sex. To develop national estimates, all analyses were weighted. Among 2,517,639 discharges with PD, 29,820 (1.2%) received DBS, and among 652,935 discharges with ET, 11,885 (1.8%) received DBS. Amid the PD cases, Black patients (n = 405 [0.2%], OR 0.16, 95% CI 0.12-0.20) were less likely than White patients (n = 23,975 [1.2%]) to receive DBS treatment, as were Hispanic patients (n = 1965 [1.1%], OR 0.76, 95% CI 0.65-0.88), whereas Asian/Pacific Islander patients (n = 855 [1.5%]) did not statistically differ from White patients. Amid the ET cases, Black (n = 230 [0.8%], OR 0.39, 95% CI 0.27-0.56), Hispanic (n = 215 [1.0%], OR 0.39, 95% CI 0.28-0.55), and Asian/Pacific Islander (n = 55 [1.0%], OR 0.51, 95% CI 0.28-0.93) patients were less likely than White patients (n = 10,440 [1.9%]) to receive DBS. Females were less likely than males to receive DBS for PD (OR 0.69, p < 0.0001) or ET (OR 0.70, p < 0.0001). The authors describe significant racial and sex-based differences in the utilization of DBS for the treatment of PD and ET. Further research is required to ascertain the causes of these disparities, as well as any differences in access to specialty neurosurgical care and referral for neuromodulation approaches.